Aurobindo posts landmark results in Q2

16108 Investors following Aurobindo Pharm. Share this News with them.

0

Like this story, share it with millions of investors on M3

Aurobindo posts landmark results in Q2

Aurobindo posts landmark results in Q2. Highest ever Revenues, EBIDTA & PAT. Revenue exceeds Rs 5 Bio and grows by 55%.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Aurobindo Pharma Q2 net profit up at Rs 54.6cr Aurobindo Pharma Q2 net seen up 6.19% at Rs 38.65cr Aurobindo gets MEB Netherlands approval in Mirtazapine Aurobindo gets FDA nod for AIDS drug ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited has registered a Total income of Rs. Million 5067 (Rs. 3271 million), EBITDA of Rs. 958 million (Rs.291million) and PAT of Rs. 546 million (Rs. 36 million) for the quarter ended 30th June 2006.

During the quarter the TOTAL income, EBITDA and PAT have shown a growth of 55%, 229% and 1417% respectively as compared to the corresponding quarter of previous year. The operating margin (EBITDA) and PAT have risen to 19% (9%) and 11% (1%) respectively.

Aurobindo's thrust into regulated markets and formulation business has contributed to the improved performance.

The formulations sales have grown by 258% and now constitute 28% total sales. The contribution of SSPs, Cephalosporins, Antivirals & other APIs to total sales now stand at 23%, 30% and 19% respectively reflecting a decisive improvement in the dosage formulations business.

Export sales have grown by 86% and constitute 58%(47%) of total sales. The exports have shown significant improvement across all markets. The contribution of Americas, Europe & Africa/CIS/Asia to the total exports now stand at 27%, 27% & 46% respectively.

Contd on page 2....